340B program federal administrators told health care providers attending the 340B Coalition winter conference in San Diego today that they are behind them in the battle with drug manufacturers over accessing 340B pricing in the contract pharmacy setting.
The U.S. Health and Human Services Department (HHS) “knows that your clinics and hospitals work with very limited resources to confront the most intractable health problems facing our most vulnerable and isolated patient populations—as has been evident in response to the COVID pandemic,” U.S Assistant Surgeon General Krista Pedley said during remarks at the 340B Coalition annual winter conference. Pedley, director of the U.S. Health Resources and Services Administration (HRSA) Office of Special Health Initiatives (OSHI), was joined by Michelle Herzog, acting director of OSHI’s Office of Pharmacy Affairs (OPA), the HRSA unit directly responsible for 340B.
340B program federal administrators told health care providers attending the 340B Coalition winter conference in San Diego today that they are behind them in the battle with drug manufacturers over accessing 340B pricing in the contract pharmacy setting.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
